RP
HAE icon

Riverwater Partners’s Haemonetics HAE Stock Holding History

Riverwater Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.57M Buy
47,645
+1,593
+3% +$102K 1.06% 22
2026
Q1 		$2.6M Buy
46,052
+15,041
+49% +$980K 0.87% 37
2025
Q4 		$2.49M Buy
31,011
+5,231
+20% +$351K 0.96% 27
2025
Q3 		$1.26M Sell
25,780
-19,143
-43% -$1.18M 0.52% 61
2025
Q2 		$3.35M Sell
44,923
-5,091
-10% -$337K 1.58% 9
2025
Q1 		$3.18M Sell
50,014
-365
-0.7% -$24.8K 1.63% 9
2024
Q4 		$3.93M Buy
50,379
+5,538
+12% +$445K 1.91% 8
2024
Q3 		$3.56M Buy
44,841
+29,109
+185% +$2.35M 1.77% 10
2024
Q2 		$1.3M Sell
15,732
-73
-0.5% -$6.42K 0.96% 23
2024
Q1 		$1.35M Buy
15,805
+21
+0.1% +$1.65K 0.99% 22
2023
Q4 		$1.35M Buy
15,784
+231
+1% +$20K 1.06% 17
2023
Q3 		$1.39M Sell
15,553
-162
-1% -$14.5K 1.27% 13
2023
Q2 		$1.34M Buy
15,715
+4,499
+40% +$380K 1.19% 16
2023
Q1 		$928K Buy
11,216
+2,098
+23% +$170K 0.85% 25
2022
Q4 		$717K Buy
+9,118
New +$733K 0.61% 48

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Riverwater Partners's HAE Position: Q2 2026 in Review

Riverwater Partners increased its Haemonetics (HAE) stake by 3.5% in Q2 2026, buying an estimated $102K and bringing the position to 47,645 shares worth $3.57M. The position accounts for 1.06% of the portfolio, ranked #22.

Riverwater Partners first reported a position in HAE in Q4 2022 and has held it in 15 quarters since. The position peaked at $3.93M in Q4 2024. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Riverwater Partners held 47,645 shares of Haemonetics worth $3.57M as of Q2 2026.
  • Riverwater Partners bought 1,593 Haemonetics shares in Q2 2026, an estimated $102K.
  • Haemonetics made up 1.06% of Riverwater Partners's portfolio in Q2 2026, its #22 holding.
  • Riverwater Partners first reported a position in Haemonetics in Q4 2022 and has held it in 15 quarters since.
  • Riverwater Partners's Haemonetics position peaked at $3.93M in Q4 2024.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Riverwater Partners's 13F filing for Q2 2026, filed 14 Aug 2026.